Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03671850
Other study ID # VT-EBV-201
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date April 9, 2019
Est. completion date June 3, 2024

Study information

Verified date March 2022
Source ViGenCell Inc.
Contact Dae-Hee Sohn
Phone 82-70-4348-7527
Email goriest@vigencell.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study aims to evaluate the efficacy and safety of VT-EBV-N (EBV-CTL) administration in ENKL patients after complete remission (CR). This is to prove the effect of VT-EBV-N (EBV-CTL) in prevention of ENKL relapse compared to placebo, by checking the primary endpoint of DFS rate (disease free survival, no relapse or death after randomization) at 2 years (103 weeks) for the last subject enrolled. 50% of the subjects will be administered VT-EBV-N (EBV-CTL), while the remaining subjects will be administered a placebo.


Description:

NK/T-cell lymphoma is a malignant tumor originating in NK cells and T lymphocytes. ENKL is associated with Epstein-Barr virus (EBV) infection and typically occurs in the nasal area, being termed ENKL, nasal type.EBV is a common virus in the herpes family. EBV infection in patients with lowered immunity such as those with Acquired Immune Deficiency Syndrome or those taking immunosuppressants after bone marrow transplant may induce lymphoproliferative diseases or cancer. VT-EBV-N (EBV-CTL) is a cytotoxicity T lymphocyte (CTL) targeting EBV expressed tumor cells indicated for ENKL. Antigen-presenting cells derived from the patient's own blood is used to activate T-cells in a test tube to recognize EBV, which are then expanded in vitro and infused into the patient's body. Targeted immunotherapy using EBV-CTL is a safe form of treatment that can improve long-term disease-free survival rates by boosting antitumor immunity without affecting other tissues apart from tumor cells.


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date June 3, 2024
Est. primary completion date December 4, 2023
Accepts healthy volunteers No
Gender All
Age group 19 Years to 75 Years
Eligibility Inclusion Criteria: 1. EBV positive extranodal NK/T cell lymphoma (ENKL) patients pathologically confirmed according to WHO classification at first diagnosis 2. Patients whose complete remission (CR) has been confirmed within 6 months before screening and maintained, presenting high risk of relapse due to one or more of the following 1) Patients who are EBV detectable at initial diagnosis, with one or more of the following high risk factors 60 years of age or older, Ann Arbor stage II ~ IV, non-nasal type disease, local invasiveness (defined with T3 or T4), elevated LDH (> upper limit of normal)) 2) Patients confirmed to have EBV DNAemia (> 2000 copies/ml) during or after treatment 3) Patients who achieved remission from secondary or greater remission induction therapy after the failure of primary remission induction, or achieved remission after relapse 3. 19 years and above to 75 years and below 4. Patients with ECOG performance criteria score of 0 to 2 5. Patients with acceptable hematopoietic function (ANC = 1.5 x 109 /L, PLT = 100 x 109 /L, Hb = 9 g/dL) 6. Patients with acceptable liver function (total bilirubin < 2 x upper limit of normal, AST/ALT < 3 x upper limit of normal) 7. Patients with renal function of eGFR > 50 or better 8. Patients with life expectancy of 6 or longer 9. Patients who have agreed to use two different types of birth control during the study period (Females of childbearing age or within 2 years after menopause have to show negative results in urine pregnancy test) (E.g., dual contraception using oral contraceptives, contraceptive implant, contraceptive injection, or contraceptive patch combined with intrauterine device, spermicide foam or gel, contraceptive film, vaginal diaphragm, cervical cap, condom, etc.) 10. Patients who have voluntarily given written consent to participate in this study Exclusion Criteria: 1. Other pathological classifications of nasal cavity lymphoma than ENKL at initial diagnosis 2. Patients with ENKL that has invaded the central nervous system 3. Patients in PR, SD or PD state, not complete remission (CR) 4. Patients who cannot generate EBV-CTL 5. Patients who have received allogeneic stem cell transplantations 6. Patients with severe or uncontrolled medical disorders(diabetes exceeding HbA1C9%, severe hypertension exceeding 180/110 mmHg, heart failure of NYHA class ? or ?, myocardial infarction diagnosed within 6 months prior to screening) 7. Patients with apparent infection (HIV infection, chronic hepatitis B, chronic hepatitis C, active tuberculosis, etc.) 8. Patients with malignant tumors or previous history of malignant tumors except completely recovered non-melanoma skin cancer or stage 0 (in situ) cervical carcinoma 9. Patients currently receiving treatment for ENKL such as chemotherapy, hormone therapy, or immunotherapy 10. Patients with hypersensitivity to the investigational product or pretreatment products, including cryoprotectants

Study Design


Intervention

Biological:
VT-EBV-N
Epstein-barr virus human cytotoxic T lymphocytes (EBV-CTL)
Other:
Placebo
Peripheral blood mononuclear cell, PBMC

Locations

Country Name City State
Korea, Republic of Inje University Busan Paik Hospital Busan
Korea, Republic of Keimyung University Daegu Dongsan Hospital Daegu
Korea, Republic of Hallym Univ. Medical Center Gyeonggi-do
Korea, Republic of Chonnam National University Hwasun Hospital Hwasun
Korea, Republic of Konkuk University Medical Center Seoul
Korea, Republic of Seoul National University Hospital Seoul
Korea, Republic of Seoul St.Mary's Hospital Seoul
Korea, Republic of Severance Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
ViGenCell Inc.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary No relapse or death due to any reason after randomization Randomization (8 weeks before administration) ~ 116 weeks after treatment period
Secondary No death after randomization Randomization (8 weeks before administration) ~ 116 weeks after treatment period
Secondary No relapse or death due to any reason after randomization Randomization (116 weeks after treatment period) ~
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04526834 - Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma Phase 1
Recruiting NCT05377827 - Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies Phase 1
Recruiting NCT04917250 - GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma Phase 2
Recruiting NCT06406556 - Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL Phase 2
Not yet recruiting NCT04337593 - Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL Phase 2
Active, not recruiting NCT04414163 - A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type Phase 2
Not yet recruiting NCT05700448 - Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma Phase 3
Completed NCT03246750 - B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma Phase 1/Phase 2
Not yet recruiting NCT03598959 - Tofacitinib Combined With Chidamide in R/R ENKTCL Phase 2
Recruiting NCT00725231 - Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP Phase 3
Recruiting NCT04554511 - Prognostic Nomogram of Extranodal NK/T-cell Lymphoma
Completed NCT03493451 - Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms Phase 2
Recruiting NCT04279379 - Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma Phase 2
No longer available NCT05131438 - An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)